Drug Trial Radar · NCT01677910
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Jan 8, 2013
Primary completion
Mar 21, 2016
Study completion Mar 21, 2016
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.
Conditions
- Carcinoid Syndrome
Interventions
Telotristat etiprateDrug
Telotristat etiprate tablets.
Placebo-matching telotristat etiprateDrug
Placebo-matching telotristat etiprate tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 WeeksTime frame: Baseline and 12 Weeks
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Double-Blind Treatment Period (Up to 17.6 Weeks)
- Number of Participants With TEAEs in the Open-Label Extension PeriodTime frame: First dose of study drug to within 30 days of last dose of study drug in the Open-Label Extension Period (Up to 54.3 Weeks)
Locations
75 sites in 12 countries. Site status is shown where the registry gives one.
Lexicon Investigational Site
Mobile, Alabama
Lexicon Investigational Site
Palo Alto, California
Lexicon Investigational Site
San Francisco, California
Lexicon Investigational Site
Orlando, Florida
Lexicon Investigational Site
Iowa City, Iowa
Lexicon Investigational Site
Lexington, Kentucky
Lexicon Investigational Site
Kenner, Louisiana
Lexicon Investigational Site
Boston, Massachusetts
Lexicon Investigational Site
Boston, Massachusetts
Lexicon Investigational Site
Omaha, Nebraska
Lexicon Investigational Site
Buffalo, New York
Lexicon Investigational Site
New York, New York
Lexicon Investigational Site
Durham, North Carolina
Lexicon Investigational Site
Philadelphia, Pennsylvania
Lexicon Investigational Site
Fort Worth, Texas
Lexicon Investigational Site
Houston, Texas
Lexicon Investigational Site
McAllen, Texas
Lexicon Investigational Site
Woodville South, Australia
Lexicon Investigational Site
Kogara, New South Wales, Australia
Lexicon Investigational Site
Saint Leanoards, New South Wales, Australia
Lexicon Investigational Site
Herston, Queensland, Australia
Lexicon Investigational Site
Fitzroy, Victoria, Australia
Lexicon Investigational Site
Freemantle, Western Australia, Australia
Lexicon Investigational Site
Edegem, Belgium
Lexicon Investigational Site
Ghent, Belgium
Lexicon Investigational Site
Yvoir, Belgium
Lexicon Investigational Site
Calgary, Alberta, Canada
Lexicon Investigational Site
Halifax, Nova Scotia, Canada
Lexicon Investigational Site
Clichy, France
Lexicon Investigational Site
Lille, France
Lexicon Investigational Site
Lyon, France
Lexicon Investigational Site
Marseille, France
Lexicon Investigational Site
Strasbourg, France
Lexicon Investigational Site
Villejuif, France
Lexicon Investigational Site
Bad Berka, Germany
Lexicon Investigational Site
Berlin, Germany
Lexicon Investigational Site
Essen, Germany
Lexicon Investigational Site
Hamburg, Germany
Lexicon Investigational Site
Heidelberg, Germany
Lexicon Investigational Site
Lübeck, Germany
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.